Alkermes plc
ALKS
주식 순위
#2629
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
주가
$43.05
마지막 동기화: 2026-10-19
시가총액
$7.22B
변동 (1일)
4.43%
변동 (1년)
38.95%
국가
IE
거래 Alkermes plc (ALKS)
카테고리
Healthcare
Alkermes plc (ALKS)의 매출
Jun 2026 기준 매출 TTM: $1.67B
Alkermes plc의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.67B입니다. 2023년에 회사는 $1.66B의 수익을 올렸으며 이는 2022년의 $1.11B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Alkermes plc의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.67B | 7.06% |
| 2024 | $1.56B | -6.36% |
| 2023 | $1.66B | 49.61% |
| 2022 | $1.11B | -5.28% |
| 2021 | $1.17B | 13.00% |
| 2020 | $1.04B | -11.29% |
| 2019 | $1.17B | 7.01% |
| 2018 | $1.09B | 21.13% |
| 2017 | $903.37M | 21.15% |
| 2016 | $745.69M | 18.68% |
| 2015 | $628.34M | 1.54% |
| 2014 | $618.79M | 7.51% |
| 2013 | $575.55M | 0.00% |
| 2012 | $575.55M | 47.59% |
| 2011 | $389.98M | 108.95% |
| 2010 | $186.64M | 4.69% |
| 2009 | $178.28M | -45.45% |
| 2008 | $326.84M | 35.78% |
| 2007 | $240.72M | 0.31% |
| 2006 | $239.97M | 44.04% |
| 2005 | $166.60M | 118.85% |
| 2004 | $76.13M | 94.92% |
| 2003 | $39.05M | -17.37% |
| 2002 | $47.27M | -12.63% |
| 2001 | $54.10M | -3.44% |
| 2000 | $56.03M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 657.01% |
US
|
|
| $2.23B | 33.60% |
US
|
|
| $15.74B | 844.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 261.06% |
NL
|
